The company manufactures and sells a wide range of agricultural chemicals, including pesticides, fungicides, and fertilizers, to farmers and distributors across India and international markets.
The company operates in a highly fragmented and regulated industry where it lacks significant pricing power, as evidenced by low net margins of 3.2%. While product registrations with the Central Insecticides Board provide a minor regulatory barrier, the low returns on equity suggest no durable competitive advantage or cost leadership.
Management has focused on capacity expansion and backward integration, including the acquisition of subsidiary Hetban Spechem. However, the negative cash conversion and reliance on external debt to fund growth indicate that reinvested capital is not yet generating sufficient organic cash flow.
The collapse was driven by a liquidity crisis as the negative cash conversion cycle finally exhausted the company's credit lines, exacerbated by the high debt-to-equity ratio. While management chased growth through backward integration, the capital was trapped in bloated inventory and receivables that never turned into cash. The situation turned terminal when the significant related-party transactions, which already accounted for over 60% of turnover, were revealed to be a mechanism for siphoning value rather than genuine trade, leading to a total loss of investor confidence and a collapse in the share price.
RichFakir rates Crop Life Science Ltd's business quality as poor — 35/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Crop Life Science Ltd is trading about 60% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Crop Life Science Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Crop Life Science Ltd's fair value is about ₹54 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →